Dianthus Therapeutics Inc. has joined the recent trend of companies licensing therapies in development from China. The company will pay as much as $1 billion to Nanjing Leads Biolabs Co. Ltd. for DNTH-212, a bifunctional BDCA2 and BAFF/APRIL inhibitor to treat autoimmune disorders. The payment comprises $30 million up front and some near-term milestones, plus an $8 million milestone for getting a phase I study underway. Leads Biolabs is in line to bring in another $962 million in milestones and royalties.

Dianthus Therapeutics Inc. has joined the recent trend of companies licensing therapies in development from China. The company will pay as much as $1 billion to Nanjing Leads Biolabs Co. Ltd. for DNTH-212, a bifunctional BDCA2 and BAFF/APRIL inhibitor to treat autoimmune disorders. The payment comprises $30 million up front and some near-term milestones, plus an $8 million milestone for getting a phase I study underway. Leads Biolabs is in line to bring in another $962 million in milestones and royalties.

In vaccine development, one might think that targeting multiple epitopes increases the likelihood of improving outcomes. However, when several immunogens are administered together, the immune system does not always generate antibodies against all of them. Two parallel studies have overcome this challenge by using multiple simultaneous immunogens against HIV, effectively triggering various types of broadly neutralizing antibody (bnAb) precursors in two different preclinical animal models.

Researchers from Cincinnati Children’s Hospital Medical Center and collaborating institutions in the U.S. have developed a novel approach using allergen-encoding mRNA encapsulated in lipid nanoparticles (LNPs) for both therapy and prevention of allergic responses.

Biopharma companies announced $73.38 billion in deals from 240 transactions during the third quarter (Q3) of 2025, bringing the year-to-date total to $212.44 billion, up from $149.87 billion in the same period of 2024. The total marks the highest deal value through Q3 ever recorded by BioWorld.

Dianthus Therapeutics Inc. has joined the recent trend of companies licensing therapies in development from China. The company will pay as much as $1 billion to Nanjing Leads Biolabs Co. Ltd. for DNTH-212, a bifunctional BDCA2 and BAFF/APRIL inhibitor to treat autoimmune disorders.

With $70 million in hand, Excellergy Inc. is ready to advance its lead candidate for allergic diseases into clinical trials. The series A round was led by Samsara Biocapital with co-investments from Red Tree Venture Capital and Decheng Capital.

Japan’s investor community is ramping up both inbound and outbound investment to create a cross-border fertile hub of innovation in Japan, investors said during a panel discussion at Bio Japan 2025 held in Yokohama Oct. 8 to 10.

Bio Japan 2025 was abuzz with the news that Japan has once again snagged the Nobel Prize in Physiology or Medicine, with Shimon Sakaguchi winning for his discovery of a subtype of CD4-expressing T cells that affect the immune response. Earlier today, Susumu Kitagawa snatched the second Nobel Prize for Japan, this time in chemistry. Both Nobel Prize winners were professors at Kyoto University.